Henry Schein (HSIC) Stock Forecast, Price & News

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

Is Henry Schein a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Henry Schein stock.
View analyst ratings for Henry Schein or view top-rated stocks.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Henry Schein.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings data on Tuesday, May, 3rd. The company reported $1.30 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.09. The business had revenue of $3.18 billion for the quarter, compared to the consensus estimate of $3.12 billion. Henry Schein had a net margin of 5.11% and a trailing twelve-month return on equity of 15.70%. Henry Schein's revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.24 EPS.
View Henry Schein's earnings history.

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Shares of Henry Schein split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its board has approved a stock buyback plan on Thursday, May 13th 2021, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $4.75-$4.91 for the period, compared to the consensus earnings per share estimate of $4.86. The company issued revenue guidance of $13.02 billion-$13.39 billion, compared to the consensus revenue estimate of $13.14 billion.

What price target have analysts set for HSIC?

6 analysts have issued 12-month price targets for Henry Schein's stock. Their forecasts range from $72.00 to $103.00. On average, they expect Henry Schein's share price to reach $94.40 in the next year. This suggests a possible upside of 13.1% from the stock's current price.
View analysts' price targets for Henry Schein or view top-rated stocks among Wall Street analysts.

Who are Henry Schein's key executives?

Henry Schein's management team includes the following people:

• Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 72, Pay $5.02M) (LinkedIn Profile)
• Mr. James P. Breslawski, Exec. Vice Chairman & Pres (Age 68, Pay $2M) (LinkedIn Profile)
• Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 65, Pay $1.68M)
• Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Exec. Director (Age 69, Pay $1.55M)
• Mr. Mark E. Mlotek, Exec. VP, Chief Strategic Officer & Exec. Director (Age 66, Pay $1.49M) (LinkedIn Profile)
• Mr. Ronald N. South, Chief Accounting Officer & VP of Corp. Fin. (Age 60)
• Mr. Christopher Pendergast, Sr. VP & CTO (Age 58)
• Graham Stanley, VP of Investor Relations & Strategic Fin. Project Officer
• Mr. Walter Siegel, Sr. VP & Chief Legal Officer (Age 62) (LinkedIn Profile)
• John Lee, VP of Global Compensation & Benefits

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Henry Schein's key competitors?

Some companies that are related to Henry Schein include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Patterson Companies (PDCO) and Owens & Minor (OMI).
View all of HSIC's competitors.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.11%), BlackRock Inc. (9.13%), State Street Corp (5.06%), Invesco Ltd. (2.95%), American Century Companies Inc. (2.62%) and Pendal Group Ltd (2.25%). Company insiders that own Henry Schein stock include Deborah Derby, Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Scott Philip Serota, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein.

Which institutional investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Invesco Ltd., Woodline Partners LP, Sprucegrove Investment Management Ltd., Sei Investments Co., Ardevora Asset Management LLP, Renaissance Technologies LLC, and Qube Research & Technologies Ltd. Company insiders that have sold Henry Schein company stock in the last year include Mark E Mlotek, Michael S Ettinger, Stanley M Bergman, and Walter Siegel.
View insider buying and selling activity for Henry Schein or view top insider-selling stocks.

Which institutional investors are buying Henry Schein stock?

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Pendal Group Ltd, American Century Companies Inc., Pzena Investment Management LLC, BlackRock Inc., APG Asset Management N.V., Vanguard Group Inc., Skandinaviska Enskilda Banken AB publ , and Boston Trust Walden Corp. Company insiders that have bought Henry Schein stock in the last two years include Deborah Derby, and Scott Philip Serota.
View insider buying and selling activity for Henry Schein or or view top insider-buying stocks.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $83.45.

How much money does Henry Schein make?

Henry Schein has a market capitalization of $11.52 billion and generates $12.40 billion in revenue each year. The company earns $631.23 million in net income (profit) each year or $4.599990 on an earnings per share basis.

How many employees does Henry Schein have?

Henry Schein employs 21,600 workers across the globe.

Does Henry Schein have any subsidiaries?

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, Maddox Practice Group, Maravet, Marrodent, Medivet, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

When was Henry Schein founded?

Henry Schein was founded in 1932.

What is Henry Schein's official website?

The official website for Henry Schein is www.henryschein.com.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500, via email at [email protected], or via fax at 631-843-5541.